Other Facilities
- Last Updated On :
Diagnostic Facility
Gamma Camera Imaging:
Department is equipped with 5 Gamma cameras including 3 dual head SPECT systems. All types of nuclear medicine investigation are performed in these imaging systems.
Non-Imaging diagnostic facilities:
Thyroid uptake probe, gamma ray spectrometers, Liquid Scintillation Counter are available for in-vivo and in-vitro studies.
PET facility:
Cyclotron and radiochemistry facility:
Department has 11 MeV cyclotron (CTI Inc.) for the production of positron emitters (such as 18F, 15O,13N,11C) and well equipped Radio chemistry laboratory for producing positron emitting radiopharmaceuticals.
PET/CT: State of the art PET/CT (Biograph) imaging facility is now available in the department at AIIMS. The most widely used PET radiopharmaceutical 18F-FDG is being routinely used at our centre. The CT not only provides the high contrast anatomical images but also provides attenuation map for attenuation correction in PET imaging. This modality has its role in Oncology, cardiology and neurology with more than 80% application in oncology for staging, monitoring treatment response, in differentiating benign and malignant lesion and restaging. It also has a role for radio therapy treatment planning.
All the patients are now getting the advantage of this new and emerging imaging modality. More than 2400 patients have already been investigated on this new imaging facility till September 2006.
Other PET radiopharmaceuticals using 15O, 13N, and 11C are be used in near future.
Department has recently procured 68Ga-68Ge generators for preparing other positron emitting radio pharmaceuticals.
Therapy:
Department has been providing radionuclide therapy facility to patients of thyrotoxicosis and cancer thyroid with 131I. There is a specifically designed isolation ward/beds for cancer thyroid patients duly approved by BARC/AERB. Other radionuclide therapy include bone pain palliation with 89Sr, 153Sm, Radiation synovectomy with 90Y and treatment of inoperable hepato cellulat carcinoma (HCC) with 188Re-lipiodol.
